Clinical Outcomes and Donor-specific Antibody Rebound 5 y After Kidney Transplant Enabled by Imlifidase Desensitization

Clinical Outcomes and Donor-specific Antibody Rebound 5 y After Kidney Transplant Enabled by Imlifidase Desensitization

Background. Imlifidase is an IgG-cleaving endopeptidase conditionally approved in Europe for desensitization of highly sensitized patients before kidney transplantation. We present 5-y outcomes and donor-specific antibody (DSA) levels for clinical trial participants from a single site who received i...

Full description

Saved in:
Bibliographic Details
Main Authors: Ian S. Jaffe, BS, Anna Runström, MSc, Vasishta S. Tatapudi, MD, Elaina P. Weldon, MSN, ACNP-BC, Cecilia L. Deterville, MS, Rebecca A. Dieter, PharmD, Robert A. Montgomery, MD, DPhil, Bonnie E. Lonze, MD, PhD, Massimo Mangiola, PhD
Format: Article
Language:English
Published: Wolters Kluwer 2025-02-01
Series:Transplantation Direct
Online Access:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001752
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001752

Similar Items